Advancing Breast Cancer Care: AI-Driven Biomarker Innovation with Diagnexia and Stratipath

We would like to invite you to an exclusive evening dedicated to the latest advancements in biomarker technology in Breast Cancer. In collaboration with Stratipath, a leader in precision medicine, Diagnexia is bringing the Stratipath Breast to the UK. As the first AI-based risk profiling solution in clinical use in Europe, Stratipath provides a rapid, broader, and more affordable alternative to gene expression testing. With Diagnexia, Stratipath can be used on its own or alongside a secondary pathology consult by world-leading experts, providing the best possible prognostic information for your patients.

Beyond thought-provoking discussions, this event offers a unique opportunity to meet the Stratipath team, discuss implementation into your practice, and connect with like-minded professionals who share your commitment to advancing patient care.  Engage in insightful conversations, exchange ideas, and build valuable professional relationships while enjoying a complimentary three-course meal.

Join us as we explore the role of AI biomarkers in revolutionising cancer care and learn how you can seamlessly integrate them into your clinical practice.   Secure your place now and be part of this discussion on the future of oncology diagnostics.

Full agenda for the event can be found HERE

‍